Quarterly report pursuant to Section 13 or 15(d)

NONCONTROLLING INTEREST

v3.10.0.1
NONCONTROLLING INTEREST
9 Months Ended
Sep. 30, 2018
Noncontrolling Interest [Abstract]  
NONCONTROLLING INTEREST

NOTE 18 – NONCONTROLLING INTEREST

 

As of September 30, 2018, Dr. Yu Zhou, director and Co-Chief Executive Officer of GenExsome, who owned 40% of the equity interests of GenExosome, which is not under the Company’s control. The following is a summary of noncontrolling interest activities in the nine months ended September 30, 2018.

 

    Amount  
Noncontrolling interest at December 31, 2017   $ (585,394 )
Net loss attributable to noncontrolling interest     (177,392 )
Foreign currency translation adjustment attributable to noncontrolling interest     (172 )
Noncontrolling interest at September 30, 2018   $ (762,958 )